Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.

What happened

Viatris said its wholly owned subsidiary, Peach Purchaser Sub Inc., began a tender offer to buy all outstanding Pacira BioSciences common shares for $36.50 per share in cash, under an October 8, 2026 merger agreement.

Confirmed

Global impact / market context

Viatris is offering cash for Pacira shares, so Pacira holders can decide whether to sell at that stated price instead of keeping the stock. For Viatris, the purchase would use company cash and brings Pacira's business under its control if enough shares are tendered.

Analyst inference

The offer follows a signed merger agreement, so the key question is whether enough Pacira holders accept the $36.50 cash price. Tender offers can change ownership quickly, and the buyer's cash outlay can affect its available cash and future spending plans.

Analyst inference

What to watch

1. Watch whether Pacira holders tender enough shares to meet the offer conditions, because the merger agreement ties the next step to completion of the tender offer. Confirmed
2. Watch for any amended offer terms, since the documents allow the Offer to Purchase and related materials to be changed or supplemented over time. Proposed
3. Watch how Viatris funds the $36.50 per-share cash payment, because a large cash outlay could reduce cash available for other uses. Analyst inference

Evidence

• Original source link unavailable